Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company.
Novel therapeutic approach – unique technology for the treatment of liver and inflammatory diseases; addressing multi-billion dollar markets
Oral drugs with proven safety and efficacy – Piclidenoson and Namodenoson are Phase III assets in psoriasis and liver cancer; Namodenoson showed strong efficacy in a Phase II NASH study; Piclidenoson is treating patients with moderate-to-severe COVID-19 in a Phase II study
Intellectual property portfolio – consists of 15 patent families issued and pending to protect different indications
Corporate partnerships – Piclidenoson and Namodenoson have been out-licensed in select territories with ~$20 million received to date and potentially up an additional $130 million plus royalties
Financially well positioned – the Company is well positioned to conduct all its clinical development programs and G&A for > 1 year
Pnina Fishman, Ph.D.
Prof. Fishman is the Scientific Founder of the Company and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center. Prof. Fishman is a very accomplished scientist and has authored or co-authored 170 publications and presented the findings of her research at many major scientific meetings. Her scientific work was the foundation on which Can-Fite was built. This scientific work has gained recognition as one of the leading approaches for next-generation therapies for cancer and other diseases. Her past managerial experience included seven years as CEO of Mor Research Application (MRA), a company that was in charge of the commercialization of intellectual property from all hospitals and research centers of Clalit Health Services, the largest healthcare provider in Israel, and was also the first clinical CRO in Israel. She was also involved in the establishment and served on the Board of Directors of several life sciences technology start-ups.